DOXAZOSIN MESYLATE - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for doxazosin mesylate and what is the scope of freedom to operate?

Doxazosin mesylate is the generic ingredient in three branded drugs marketed by Viatris, Accord Hlthcare, Actavis Elizabeth, Ani Pharms, Apotex, Aurobindo Pharma Usa, Chartwell Rx, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Nesher Pharms, Pliva, Rising, Strides Pharma, Teva, Unichem, Upsher Smith Labs, Watson Labs Inc, and Zydus Pharms, and is included in twenty-one NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for doxazosin mesylate. Thirty-one suppliers are listed for this compound.

Summary for DOXAZOSIN MESYLATE

US Patents:	0
Tradenames:	3
Applicants:	19
NDAs:	21
Drug Master File Entries:	14
Finished Product Suppliers / Packagers:	31
Raw Ingredient (Bulk) Api Vendors:	106
Clinical Trials:	2
Patent Applications:	3,011
Drug Prices:	Drug price trends for DOXAZOSIN MESYLATE
What excipients (inactive ingredients) are in DOXAZOSIN MESYLATE?	DOXAZOSIN MESYLATE excipients list
DailyMed Link:	DOXAZOSIN MESYLATE at DailyMed

See drug prices for DOXAZOSIN MESYLATE

Drug Sales Revenue Trends for DOXAZOSIN MESYLATE

See drug sales revenues for DOXAZOSIN MESYLATE

Recent Clinical Trials for DOXAZOSIN MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pfizer
National Heart, Lung, and Blood Institute (NHLBI)	Phase 2

See all DOXAZOSIN MESYLATE clinical trials

Pharmacology for DOXAZOSIN MESYLATE

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Medical Subject Heading (MeSH) Categories for DOXAZOSIN MESYLATE

Adrenergic alpha-1 Receptor Antagonists
Antihypertensive Agents

Anatomical Therapeutic Chemical (ATC) Classes for DOXAZOSIN MESYLATE

C02CA	Alpha-adrenoreceptor antagonists
C02C	ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

US Patents and Regulatory Information for DOXAZOSIN MESYLATE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs Inc	DOXAZOSIN MESYLATE	doxazosin mesylate	TABLET;ORAL	075426-004	Oct 18, 2000		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Actavis Elizabeth	DOXAZOSIN MESYLATE	doxazosin mesylate	TABLET;ORAL	075574-004	Oct 18, 2000		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ani Pharms	DOXAZOSIN MESYLATE	doxazosin mesylate	TABLET;ORAL	075432-002	Oct 18, 2000		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for DOXAZOSIN MESYLATE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-003	Nov 2, 1990	⤷ Sign Up	⤷ Sign Up
Viatris	CARDURA XL	doxazosin mesylate	TABLET, EXTENDED RELEASE;ORAL	021269-002	Feb 22, 2005	⤷ Sign Up	⤷ Sign Up
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-002	Nov 2, 1990	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.